CN1101680C - 噻吩并三唑并二氮杂䓬增加载脂蛋白a－1含量的用途 - Google Patents

噻吩并三唑并二氮杂䓬增加载脂蛋白a－1含量的用途 Download PDF

Info

Publication number
CN1101680C
CN1101680C CN96196835A CN96196835A CN1101680C CN 1101680 C CN1101680 C CN 1101680C CN 96196835 A CN96196835 A CN 96196835A CN 96196835 A CN96196835 A CN 96196835A CN 1101680 C CN1101680 C CN 1101680C
Authority
CN
China
Prior art keywords
apolipoprotein
compound
content
day
plasma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN96196835A
Other languages
English (en)
Chinese (zh)
Other versions
CN1195989A (zh
Inventor
H·肯彭
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of CN1195989A publication Critical patent/CN1195989A/zh
Application granted granted Critical
Publication of CN1101680C publication Critical patent/CN1101680C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN96196835A 1995-09-09 1996-08-30 噻吩并三唑并二氮杂䓬增加载脂蛋白a－1含量的用途 Expired - Fee Related CN1101680C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP95114163.9 1995-09-09
EP95114163 1995-09-09

Publications (2)

Publication Number Publication Date
CN1195989A CN1195989A (zh) 1998-10-14
CN1101680C true CN1101680C (zh) 2003-02-19

Family

ID=8219597

Family Applications (1)

Application Number Title Priority Date Filing Date
CN96196835A Expired - Fee Related CN1101680C (zh) 1995-09-09 1996-08-30 噻吩并三唑并二氮杂䓬增加载脂蛋白a－1含量的用途

Country Status (14)

Country Link
US (1) US5854238A (https=)
EP (1) EP0853480B1 (https=)
JP (1) JPH11512107A (https=)
KR (1) KR19990044460A (https=)
CN (1) CN1101680C (https=)
AT (1) ATE230600T1 (https=)
AU (1) AU725249B2 (https=)
BR (1) BR9610390A (https=)
CA (1) CA2230477A1 (https=)
DE (1) DE69625696T2 (https=)
DK (1) DK0853480T3 (https=)
ES (1) ES2188783T3 (https=)
TR (1) TR199800406T1 (https=)
WO (1) WO1997009048A1 (https=)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6004925A (en) * 1997-09-29 1999-12-21 J. L. Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6518412B1 (en) * 1997-09-29 2003-02-11 Jean-Louis Dasseux Gene therapy approaches to supply apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6253569B1 (en) * 1999-05-07 2001-07-03 James J. Hall Portable storage unit for game animals
US7144862B2 (en) 2000-08-24 2006-12-05 The Regents Of The University Of California Orally administered peptides to ameliorate atherosclerosis
US6664230B1 (en) 2000-08-24 2003-12-16 The Regents Of The University Of California Orally administered peptides to ameliorate atherosclerosis
US7148197B2 (en) * 2000-08-24 2006-12-12 The Regents Of The University Of California Orally administered small peptides synergize statin activity
US7166578B2 (en) 2000-08-24 2007-01-23 The Regents Of The University Of California Orally administered peptides synergize statin activity
US7199102B2 (en) * 2000-08-24 2007-04-03 The Regents Of The University Of California Orally administered peptides synergize statin activity
US7723303B2 (en) * 2000-08-24 2010-05-25 The Regents Of The University Of California Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
US8568766B2 (en) 2000-08-24 2013-10-29 Gattadahalli M. Anantharamaiah Peptides and peptide mimetics to treat pathologies associated with eye disease
US7429593B2 (en) 2001-09-14 2008-09-30 Shionogi & Co., Ltd. Utilities of amide compounds
US20040235877A1 (en) 2001-09-14 2004-11-25 Natsuki Ishizuka Novel use of tricyclic compound
US8124625B2 (en) 2001-09-14 2012-02-28 Shionogi & Co., Ltd. Method of enhancing the expression of apolipoprotein AI using olefin derivatives
US6930085B2 (en) * 2002-04-05 2005-08-16 The Regents Of The University Of California G-type peptides to ameliorate atherosclerosis
WO2006063132A2 (en) 2004-12-06 2006-06-15 The Regents Of The University Of California Methods for improving the structure and function of arterioles
AU2008296478B9 (en) 2007-08-28 2015-03-19 The Uab Research Foundation Synthetic apolipoprotein E mimicking polypeptides and methods of use
US8557767B2 (en) 2007-08-28 2013-10-15 Uab Research Foundation Synthetic apolipoprotein E mimicking polypeptides and methods of use
US8569288B2 (en) 2008-10-30 2013-10-29 Circomed Llc Thienotriazolodiazepine derivatives active on apo A
MX354217B (es) 2010-05-14 2018-02-19 Dana Farber Cancer Inst Inc Composiciones y metodos para el tratamiento de leucemia.
WO2011143651A1 (en) * 2010-05-14 2011-11-17 Dana-Farber Cancer Institute, Inc. Compositions and methods for modulating metabolism
PL2902030T3 (pl) 2010-05-14 2017-07-31 Dana-Farber Cancer Institute, Inc. Związki tienotriazolodiazepinowe do leczenia nowotworu
CN103180318B (zh) 2010-05-14 2017-05-10 达那-法伯癌症研究所 雄性避孕组合物以及使用方法
AU2014292888B2 (en) 2013-07-25 2018-03-22 Dana-Farber Cancer Institute, Inc. Inhibitors of transcription factors and uses thereof
CA2929652A1 (en) 2013-11-08 2015-05-14 Dana-Farber Cancer Institute, Inc. Combination therapy for cancer using bromodomain and extra-terminal (bet) protein inhibitors
CA2936865A1 (en) 2014-01-31 2015-08-06 Dana-Farber Cancer Institute, Inc. Diaminopyrimidine benzenesulfone derivatives and uses thereof
WO2015117087A1 (en) 2014-01-31 2015-08-06 Dana-Farber Cancer Institute, Inc. Uses of diazepane derivatives
SG11201607108XA (en) 2014-02-28 2016-09-29 Tensha Therapeutics Inc Treatment of conditions associated with hyperinsulinaemia
MX383117B (es) 2014-07-31 2025-03-13 Anji Pharmaceuticals Inc Péptidos miméticos de la apoe y mayor potencia para depurar el colesterol en plasma.
KR20170032474A (ko) 2014-08-08 2017-03-22 다나-파버 캔서 인스티튜트 인크. 디히드로프테리디논 유도체 및 그의 용도
CN106715437A (zh) 2014-08-08 2017-05-24 达纳-法伯癌症研究所股份有限公司 二氮杂环庚烷衍生物及其用途
BR112017008714A2 (pt) 2014-10-27 2017-12-19 Tensha Therapeutics Inc inibidores de bromodomínio
US10702527B2 (en) 2015-06-12 2020-07-07 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
HK1256417A1 (zh) 2015-09-11 2019-09-20 达纳-法伯癌症研究所股份有限公司 氰基噻吩并三唑并二氮杂环庚三烯及其用途
RU2018112953A (ru) 2015-09-11 2019-10-14 Дана-Фарбер Кэнсер Инститьют, Инк. Ацетамидтиенотриазолодиазепины и пути их применения
MX2018006499A (es) 2015-11-25 2018-08-01 Dana Farber Cancer Inst Inc Inhibidores de bromodominio bivalentes y usos de los mismos.
MX2020013608A (es) 2018-06-13 2021-03-09 Worg Pharmaceuticals Hangzhou Co Ltd Preparacion de derivados de triazepina condensados y su uso como inhibidores de bet.

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4155913A (en) * 1973-02-08 1979-05-22 Hoffmann-La Roche Inc. Thienotriazolodiazepine derivatives

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12303A (en) * 1973-02-08 1979-01-16 Hoffmann La Roche Thienotriazolodiazepine derivatives
JPS50100096A (https=) * 1974-01-08 1975-08-08

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4155913A (en) * 1973-02-08 1979-05-22 Hoffmann-La Roche Inc. Thienotriazolodiazepine derivatives

Also Published As

Publication number Publication date
DK0853480T3 (da) 2003-05-05
EP0853480A1 (en) 1998-07-22
DE69625696T2 (de) 2003-10-16
AU6930396A (en) 1997-03-27
KR19990044460A (ko) 1999-06-25
EP0853480B1 (en) 2003-01-08
US5854238A (en) 1998-12-29
TR199800406T1 (en) 1998-05-21
CN1195989A (zh) 1998-10-14
AU725249B2 (en) 2000-10-12
MX9801753A (es) 1998-08-30
BR9610390A (pt) 1999-07-06
ATE230600T1 (de) 2003-01-15
JPH11512107A (ja) 1999-10-19
ES2188783T3 (es) 2003-07-01
WO1997009048A1 (en) 1997-03-13
DE69625696D1 (de) 2003-02-13
CA2230477A1 (en) 1997-03-13

Similar Documents

Publication Publication Date Title
CN1101680C (zh) 噻吩并三唑并二氮杂䓬增加载脂蛋白a－1含量的用途
US6562869B1 (en) Nutritional supplement for increased energy and stamina
US6479069B1 (en) Nutritional supplement for increased energy and stamina
US5773473A (en) Creatine supplement
EP1014968B1 (en) NARINGIN AND NARINGENIN AS 3-HYDROXY-3-METHYLGLUTARYL CoA(HMG-CoA) REDUCTASE INHIBITOR
JP4699901B2 (ja) 体脂肪代謝機能と燃焼エネルギーの活用機能とを備えているダイエット用添加物質
AU2008269728B2 (en) Improving memory in subjects with mini-mental state examination of 24-26
HUT52396A (en) Therapeutic combination compositions and their use as antineoplastics
JPH07507569A (ja) ヒトの窒素保持の促進方法
US4452815A (en) Method of utilizing d,l-fenfluramine for modifying feeding behavior
US4309445A (en) d-Fenfluramine for modifying feeding behavior
US20030012827A1 (en) Omega-3 fatty acids in the treatment of depression
US6605646B2 (en) Vitamin supplement composition
JP2001233776A (ja) 学習・記憶能低下改善剤およびその用途
GB2180747A (en) Tryptophan composition for treatment of obesity
AU2020356255B2 (en) Compositions and methods using adenosylcobalamin
EA002177B1 (ru) Композиция для подавления симптомов абстиненции и тяги к алкоголю у алкоголиков и профилактики злоупотребления алкоголем у здоровых людей
AU666157B2 (en) Body tissue omega-3 fatty-acid-augmenting agent and nutrient composition containing the same
US5627152A (en) Method for increasing bodyweight
JP3020111B2 (ja) 体脂肪蓄積低減剤
US20020077349A1 (en) Method of treating age-related vision impairment
WO2003009840A1 (en) Composition comprising at least one lipase inhibitor and carnitine
US5093371A (en) Naphthyl ketone inhibitors of cholesterol esterase and their use as hypolipidemic and hypocaloric agents
MXPA98001753A (en) Use of a thenotriazolodiazepine to increase apolipoprotein levels
US20040176442A1 (en) Potassium taurate bicarbonate and ascorbate

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C19 Lapse of patent right due to non-payment of the annual fee
CF01 Termination of patent right due to non-payment of annual fee